A reference for health system and maternal care leaders on which monitoring tools serve patients in maternity care deserts.

Pulsenmore ES is a physician-prescribed home prenatal ultrasound system with FDA De Novo marketing authorization, and health systems can add it to a remote monitoring program for pregnant patients who live far from a clinic. It operates within hybrid prenatal care, which combines telehealth consultations with connected monitoring technologies and lets providers maintain clinical engagement between in-person visits. Each technology serves a complementary purpose. In-person visits remain essential for comprehensive diagnostic evaluation and for care that requires direct clinical assessment.
Scale of the maternity care desert problem
The March of Dimes 2026 report found that 34.6 percent of U.S. counties are maternity care deserts. A maternity care desert is a county with no obstetric clinicians or birthing facilities. These counties are home to 2.4 million women of reproductive age and 149,000 births a year. Women living in them travel about three times farther on average to reach labor and delivery services than women in counties with full access.
The report identified at least 96 labor and delivery unit closures across 35 states from January 2024 to May 2026. In nearly 60 percent of the affected counties, the closed unit was the only local birthing facility, and recent closures added an average of 25 minutes of travel. Combining in-person visits with telehealth and clinician-reviewed home monitoring lets health systems extend prenatal care and reduce unnecessary travel.
How Pulsenmore ES is organized
Pulsenmore ES has three parts: a handheld transducer that docks to the patient’s smartphone, an app that guides the scan, and a clinician dashboard for review. In app-guided mode, the patient scans independently and submits the scan for clinician review. In clinician-guided mode, a clinician guides the scan in real time. A physician prescribes the device.
The platform supports role-based workflows. An administrator can schedule appointments, a sonographer or midwife reviews scans and records findings, and a doctor gives the final sign-off. This frees doctors’ time for patients who need to be seen face to face. Results can be documented in the electronic medical record.
The FDA granted De Novo marketing authorization in an announcement dated November 3, 2025. The device is designed for use from week 14 through week 38 in single-fetus pregnancies.
Evidence for Pulsenmore ES
In a study of 100 women who scanned themselves in Israel, fetal heart activity was detected in 95.3 percent of cases. In the multicenter U.S. HOLA study, which supported the FDA authorization, 162 women at four institutions performed 1,370 scans. Fetal cardiac activity was assessed successfully in 99.2 percent of clinician-guided scans and 96.5 percent of app-guided scans.
A retrospective cohort found no significant association with preterm delivery or adverse neonatal outcomes among 4,460 users and 102,707 matched non-users. A randomized trial in women with previous pregnancy loss reported lower anxiety and higher maternal-fetal attachment. A Sheba pilot of hybrid care for gestational diabetes reported 97.4 percent remote visit completion. Independent studies in the Netherlands, the United Kingdom and Germany add feasibility data. Pulsenmore reports more than 270,000 home ultrasound scans performed in real-world settings.
Pulsenmore also announced a partnership with Ouma Health to add home ultrasound to a virtual maternity care platform that serves patients in maternity deserts and underserved communities.
What current clinical guidance permits
ACOG’s Clinical Consensus No. 8, published in April 2025, supports tailoring prenatal care to the patient. Michigan Medicine’s summary of the guidance describes fewer, more widely spaced visits for uncomplicated pregnancies, supplemented by telemedicine and home monitoring devices. The systematic reviews behind the consensus found no differences in maternal and neonatal outcomes among average-risk patients on targeted schedules or telemedicine compared with traditional schedules. They also found high-quality evidence for home blood pressure monitoring. Some higher-risk patients still need more frequent visits and monitoring.
Monitoring needs and the tool that serves each
| Monitoring need | Typical tool | What it covers | Role of Pulsenmore ES |
| Maternal blood pressure between visits | Home blood pressure cuff with remote review | Maternal hypertension, supported by high-quality evidence | Runs alongside |
| Fetal heart rate pattern | Fetal heart monitor with remote review | Heart rate tracing | Complementary |
| Fetal heart rate assessment | Home ultrasound reviewed by a clinician | Assessment from home-acquired ultrasound images | Core function |
| Anatomy, growth, diagnostic findings | In-person ultrasound | Full diagnostic assessment | Not replaced, stays in the pathway |
| Specialist input | Telehealth visit with a maternal-fetal medicine team | Consultation and care planning | Clinician-guided mode lets the clinician direct a scan during the visit |
Sheba Medical Center’s hospital-at-home program for high-risk pregnancy combines several of these tools in one model: daily remote visits, glucose monitoring, fetal heart tracing from INVU by Nuvo, and fetal ultrasound from Pulsenmore. It had 93 patients by February 2025.
Practical takeaways for health system leaders
First, identify the gaps in prenatal care created by distance, particularly the need for regular maternal and fetal assessments between clinic visits.
Second, build a connected care model that combines complementary technologies, based on each patient’s clinical needs.
Third, establish a clear clinical workflow, with defined responsibilities for remote review, timely communication and escalation when further evaluation is needed.
Finally, integrate remote care with essential in-person services and measure its effect on access, patient experience, clinical outcomes and healthcare resource utilization.
Pulsenmore ES compared with Butterfly iQ3 and Philips Lumify
Butterfly iQ3 and Philips Lumify are handheld devices designed for a different care model than Pulsenmore ES. The table compares the three on the criteria that decide fit.
| Criterion | Pulsenmore ES | Butterfly iQ3 | Philips Lumify |
| Who acquires the images | Pregnant patient at home, by physician prescription | Qualified and trained healthcare professional | Healthcare professional in a clinical environment |
| Who interprets | Healthcare professionals review remotely, with physician sign-off | The professional operating the device, at the point of care | The professional operating the device, at the point of care |
| Care model | Clinician-led remote prenatal care between visits | Point-of-care imaging during a clinical encounter | Point-of-care imaging during a clinical encounter |
| Clinical scope | Fetal heart rate determination, singleton pregnancies, 14 to 38 weeks | Many body regions, including cardiac, abdominal, fetal and obstetric, and gynecological imaging | A similarly broad list of applications |
| Regulatory basis | FDA De Novo decision for prescribed home use | FDA record indicating use by qualified and trained healthcare professionals | FDA record describing use by healthcare professionals in clinical environments |
| Reported real-world use | More than 270,000 home ultrasound scans | Professional-use indications | Professional-use indications |
The sources are the FDA record for Butterfly iQ3, the FDA record for Philips Lumify and the FDA De Novo decision for Pulsenmore ES. The difference is who is authorized to operate each system and how it fits the care pathway. The devices serve different pathways and do not compete for the same use.
FAQs
Q: What is a maternity care desert?
A: It is a county with no obstetric clinicians or birthing facilities. The March of Dimes 2026 report found that 34.6 percent of U.S. counties meet that definition.
Q: Does home ultrasound replace in-person ultrasound for patients far from a clinic?
A: No, it adds fetal heart rate checks between visits, and the health system keeps in-person diagnostic ultrasound in the care pathway.
Q: Can patients with limited connectivity use home ultrasound?
A: The two scanning modes have different connectivity requirements. Clinician-guided scans require a live connection with a healthcare professional. App-guided scans can be performed independently, without a live clinical session, but internet connectivity is still required to transmit scans for clinician review. Providers should assess connectivity and smartphone compatibility when determining patient eligibility.
Q: What does ACOG’s April 2025 consensus support?
A: It supports tailored visit schedules, telemedicine and home monitoring, which gives health systems a clinical basis for remote prenatal programs.
Q: Which patients can use Pulsenmore ES?
A: It is designed for use from week 14 of pregnancy and for single-fetus pregnancies. A physician prescription is required, and each device is personal and intended for one patient during one pregnancy. The treating clinician decides use based on the patient’s risk profile.
Q: What clinical evidence supports Pulsenmore ES?
A: A pivotal multicenter U.S. study of 162 women and 1,370 scans supported its FDA De Novo authorization. A real-world study in Israel compared pregnancy outcomes among 4,460 users and more than 102,000 non-users and found no significant association between home ultrasound use and adverse pregnancy outcomes. Additional published research has explored maternal anxiety, patient experience and the integration of home ultrasound into hybrid prenatal care, including studies in the Netherlands and Israel. Pulsenmore reports more than 270,000 home ultrasound scans performed in real-world settings.
Q: Is Pulsenmore ES available in the United States now?
A: Yes. Pulsenmore launched U.S. commercial operations in 2026, with initial agreements with the Center for Fetal Maternal Ultrasound in Los Angeles and TLC Perinatal Care in Maryland, followed by a partnership with Ouma Health. Providers interested in offering it can contact the company directly. Once a provider is enrolled, eligible patients can purchase the device through Pulsenmore’s website with a prescription from their healthcare provider.
Q: How does reimbursement work for Pulsenmore home ultrasound in the U.S.?
A: Pulsenmore can be integrated into existing prenatal care models. Under a common commercial approach, providers offer the device to patients for a fee and may seek reimbursement from insurers for eligible ultrasound services performed and interpreted by clinicians. Reimbursement depends on the services provided, applicable billing codes, payer policies and individual coverage arrangements. Pulsenmore works with healthcare organizations to explore clinical and commercial models that fit their practice.